Main Article Content
Background: Hepatitis B virus (HBV) infection is endemic and well documented in different locations of Nigeria among different sub-groups. Information regarding the prevalence of HBV in HIV infected women is scarce especially in Abuja, the capital city of Nigeria.
Aim: This study aimed at determining the prevalence of Hepatitis B surface antigen (HBsAg) among HIV infected women seeking for antiretroviral therapy (ART) at the National Institute for Pharmaceutical Research and Development (NIPRD), Abuja, Nigeria.
Materials and Methods: A health facility-based cross-sectional study was carried out in our laboratory from May, 2017 to March, 2019 among 1,386 recruited HIV infected women that were screened for HBsAg. Positive samples were confirmed using ELISA. Their socio-demographic data were collected using a questionnaire and written informed consent was obtained prior to study. Data were analyzed using frequency distribution table and SPSS (version 20.0).
Results: Out of the 1,386 HIV infected women tested, 114 were seropositive for HBV infection giving an infection prevalence of 8.2%. The highest prevalence (2.2%) was observed at age group 25 – 29 years and followed by (1.7%) at age groups of 20 – 24 and 35 – 39 years.
Conclusion: This finding confirms high endemic of HBV infection. We recommend that HIV infected women should be routinely screened for HBV as part of ART commencement requirement.
Federal Ministry of Health. National HIV Sero-prevalence Sentinel survey. Technical Report. 2010;5-25.
Federal Ministry of Health. National HIV Sero-prevalence Sentinel survey, Technical Report. 2015;5-19.
UNAIDS. Press release on Nigeria New Survey on HIV; 2019.
Krajden M, McNabb G, Petric M. The laboratory diagnosis of hepatitis B virus. Can J Infect Dis Med. 2005;16(2):65-72.
Doo EC, Ghany MG. Hepatitis B virology for clinicians. Med Clin North Am. 2010; 14(3):397- 408.
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current andemerging prevention and control measures. J Viral Hepat. 2004;11 (2): 97-107.
Milazzo L, Antinori S. Hepatitis virus and HIV interactions. Lancet Infect Dis. 2014; 14(11):1025-1027.
Xie J, Han Y, Qiu Z. Prevalence of hepatitis B and C viruses in HIV- positive patients inChina: a cross- sectional study. J Int AIDS Soc. 2016;19(1):20659.
Matthews PC, Beloukas A, Malik A. Prevalence and Characteristics of Hepatitis BVirus (HBV) Coinfection among HIV-Positive Women in South Africa and Botswana. PLoS One. 2015;10(7): e0134037.
WHO. Global Hepatitis Report; 2018.
Wilcox RD. Hepatitis B co-infection in pregnancy. HIV Clinician. 2010;22(1):5-6.
Nwokedi EE, Epopees MA, Dutse AI. Human immunodeficiency virus and hepatitis Bvirus co infection among patients in Kano, Nigeria. Niger J Med. 2006;15(3):227- 9.
Lesi OA, Kehinde MO, Oguh DN, Amira CO. Hepatitis B and C virus infection in Nigerian patients with HIV/AIDS. Niger Postgrad Med J. 2007;14(2):129-33.
Balogun TM, Emmanuel S, Ojerinde EF. HIV, Hepatitis B and C viruses? co-infectionamong patients in a Nigerian tertiary hospital. The Pan African Medical Journal. 2012;12:100.
Denue BA, Ajayi B, Abja AU, Bukar AA, Akawu C, Ekong E, Alkali MB. A survey of Hepatitis B and C virus prevalence in human immunodeficiency virus positive patientsin a Tertiary health institution in North Eastern Nigeria. International Journal of Medicineand Medical Sciences. 2012;4(1):13-18.
Imade GE, Sagay AS, Ugwu BT, Thacher TD, Ford RW. Seroprevalence of Hepatitis B and Human Immunodeficiency Virus infections in pregnant women in Nigeria. Journal of Medic in the Tropics. 2004; 6(2):15-21.
Joint United Nations Programme on HIV/AIDS. Report on the global AIDS epidemic. Geneva, Switzerland: UNAIDS; 2010.
Available:http://www. unaids.org/globalreport/Global_report. htm.
Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ. Influence ofhuman immunodeficiency virus infection on the course of hepatitis C virus infection: Ameta-analysis. Clin Infect Dis. 2001; 33(4):562-569.
Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology. 2002;36(1):512-513.
Zimmerman RK, Ruben FL, Ahwesh ER. Hepatitis B virus infection, Hepatitis B vaccine and Hepatitis B immune globulin. J Fam Pract. 1997;45(4):295-315.
Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, Thomas DL. HIV-1, Hepatitis B virus and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360(9349):1921-1926.
Henry O. The Free Online Encyclopaedia. 5th Edition, New York; 2008.
Uneke CJ, Ogbu O, Inyama PU, Anyanwu GI, Njoku MO, Idoko JH. Prevalence of Hepatitis-B surface antigen among blood donors and human immunodeficiency virus-infected patients in Jos, Nigeria. Mem Inst Oswaldo Cruz. 2005;100:13-6.
Centers for Disease Control and Prevention (CDC). Testing for HCV infection: An update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep. 2013;62(18):362-365.
Hoffmann CJ, Charalambous S, Martin DJ. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis. 2008;47(11):1479-85.
Franzeck FC, Ngwale R, Msongole B. Viral hepatitis and rapid diagnostic test basedscreening for HBs Ag in HIV-infected patients in rural Tanzania. PLoS One. 2013;8(3):e58468.
Soriano V, Barreiro P, Sherman KE. The changing epidemiology of liver disease in HIV patients. AIDS Rev. 2013;15(1):25-31.
Otegbayo JA, Taiwo BO, Akingbola TS. Prevalence of Hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients. Ann Hepatol. 2008;7(2): 152-6. Adewole OO, Anteyi E, Ajuwon Z. Hepatitis B and C virus co-infection in Nigerianpatients with HIV infection. J Infect Dev Ctries. 2009;3(5):369-75.
Nyirenda M, Beadsworth MB, Stephany P. Prevalence of infection with hepatitis B and C virus and coinfection with HIV in medical inpatients in Malawi. J Infect. 2008;57(1):72-7.
Diop-Ndiaye H, Touré-Kane C, Etard JF. Hepatitis B, C seroprevalence and deltaviruses in HIV-1 Senegalese patients at HAART initiation (retrospective study). J Med Virol. 2008;80(8):1332-6.
Obi RK, Umeh SC, Okurede OH, Iroagba II. Prevalence of hepatitis B virus infectionamong pregnant women in an antenatal clinic in Port Harcourt, Nigeria. Afr J Clin Exp Micro. 2006;7:78-82.
Sahaf F, Tanomand A, Montazam H, Sany AA. Seroprevalence of Hepatitis C, Hepatitis B and HIV and co-infection among pregnant women: a retrospective study in 2006 at Malekan city, Iran. Res J Med Sci. 2007;1:138-41.
Todd CS, Ahmadzai M, Atiqzai F, Miller S, Smith JM, Ghazan SA. Seroprevalence and correlates of HIV, Syphilis, and hepatitis B and C virus among intrapartum patientsin Kabul, Afghanistan. BMC Infect Dis. 2008;8:119.
Mbaawuaga EM, Enenebeaku MN, Okopi JA, Damen JG. Hepatitis B virus (HBV) infection amongpregnant women in Makurdi, Nigeria. Afr J Biomed Res. 2008; 11:155‑9.
Harry TO, Bajani MD, Moses AE. Hepatitis B virus infection among blood donorsand pregnant women in Maiduguri, Nigeria. East Afr Med J. 1994; 71: 596-7. Jombo GTA, Egah DZ, Banwat EB. Hepatitis B Virus infection in a rural Settlement of Northern Nigeria. Niger J Med. 2005; 14:425-8.
Roingeard P, Diouf A, Sankale JL, Boye C, Mboup, Diadhiou F. Perinatal transmission of hepatitis B virus infection in Senegal, West Africa. Viral Immunol. 1993;6:65-73.
Imade GE, Sagay AS, Ugwu BT, Thacher TD, Ford RW. Seroprevalence of hepatitis band HIV infections in pregnant women in Nigeria. J Med Trop. 2004;6:15-21.
Anaedobe CG, Fowotade A, Omoruyi CE, Bakare RA. Prevalence, sociodemographic features and risk factors of hepatitis B virus infection among pregnant women in Southwestern Nigeria. Pan Afr Med J. 2015;20:406.
Brandão NA, Pfrimer IA, Martelli CM, Turchi MD. Prevalence of hepatitis B and C infection and associated factors in people living with HIV in Midwestern Brazil. Braz J Infect Dis. 2015;19(4):426-30.